Pfenex Inc. awards contract for development of anthrax vaccine
Glide Pharma will use its Glide Solid Dose Injector technology in the development of the recombinant Protective Antigen against Bacillus anthacis, the virus responsible for anthrax. This approach will allow for longer storage and easier administration, two logistical concerns regarding the current anthrax vaccine.
The rPA was highly immunogenic in animal trials and produces a robust yield through a scalable production process. The project has been fully funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health and Department of Health and Human Services.
"We are pleased to award this sub-contract to Glide Pharma. Their novel formulation and delivery technology allows us to expand our anthrax vaccine program,"Pfenex CEO Bertrand C. Liang said. "Leveraging the Glide SDI technology to develop an alternative delivery method of the Pfenex anthrax vaccine further supports our efforts to provide a safe, feasible and cost-effective solution to the United States government's quest to stockpile sufficient vaccine doses to rapidly respond to an anthrax biothreat."